Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-Lung01: Izalontamab Brengitecan vs Platinum-Pemetrexed in EGFR-mutated NSCLC
NCT07100080Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 25
01
Overview
A Phase 3 trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Nov 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07100080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100080.